Core Viewpoint - The brain-machine interface (BMI) sector is experiencing significant advancements, with recent clinical trials demonstrating practical applications that could lead to commercial opportunities in the healthcare industry [1]. Industry Summary - The brain-machine concept stocks opened high, with notable increases in share prices for companies such as Brainhole Aurora (06681) rising by 10.35% to HKD 6.29 and Nanjing Panda Electronics (00553) increasing by 1.63% to HKD 4.36 [1]. - A research team from the Chinese Academy of Sciences has successfully completed three invasive brain-machine interface clinical trials, achieving breakthroughs in real-life applications [1]. - In the second clinical trial, a high-level paraplegic patient was able to control a smart wheelchair and robotic dog using brain signals, demonstrating the potential for independent mobility and object retrieval in real-life scenarios [1]. Company Summary - CITIC Securities believes that advancements in the midstream technology of the brain-machine interface industry are leading to breakthroughs in downstream applications, particularly in medical fields such as motor recovery, communication, and hearing restoration [1]. - The Chinese government and various regions have introduced multiple policies to accelerate the development of the industry, including a recent announcement from the National Healthcare Security Administration to separately list pricing for new brain-machine interface technologies [1]. - With technological innovations and policy incentives, domestic brain-machine interface companies are expected to gradually achieve commercial applications [1].
港股异动 脑机接口概念股集体高开 我国已完成三例侵入式脑机接口临床试验